2. Academic Validation
  3. Fragment-Based Discovery of an Oral Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine

Fragment-Based Discovery of an Oral Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine

  • J Med Chem. 2025 Jul 24;68(14):14919-14944. doi: 10.1021/acs.jmedchem.5c01127.
Naohide Morita 1 2,  Noritaka Furuya 1,  Takaki Momose 1,  Atsushi Kondo 1,  Takehiro Ishikawa 1,  Isao Wanajo 1,  Michiyo Nishikawa 1,  Motoyasu Ozawa 1,  Masaoki Kajino 1,  Hiroshi Harada 1,  Akane Matsuzawa 1,  Akihiro Tsuchioka 1,  Hidemasa Hikawa 2,  Isao Azumaya 2
Affiliations

Affiliations

  • 1 Central Research Laboratory, Kissei Pharmaceutical Co., Ltd., 4365-1 Hotakakashiwabara, Azumino, Nagano 399-8304, Japan.
  • 2 Faculty of Pharmaceutical Sciences, Toho University, 2-2-1, Miyama, Funabashi, Chiba 274-8510, Japan.
PMID: 40608025 DOI: 10.1021/acs.jmedchem.5c01127
Abstract

Calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated clinical efficacy in the treatment of migraine. In this study, we performed surface plasmon resonance-based fragment screening to identify various site Binders and estimated their binding modes based on surface plasmon resonance and nuclear magnetic resonance studies using mutated CGRP receptors. Two fragment hits were merged and optimized to create compound 15, which showed good oral bioavailability in rats, attractive preclinical properties overall, and robust activity in a primate model of CGRP-induced facial blood flow.

Figures
Products